• Recurring revenue base represents 85% of total revenue and 78% of OPEX
• Reduced operating expenses by 6% as part of disciplined cost management
• Strong financial position with A$18.5M in cash and no debt

Mach7 Technologies Ltd reported its first half FY26 financial results, showcasing progress in its business transformation. The company's recurring revenue base now represents 85% of total revenue and 78% of operating expenses, reflecting the scalability and efficiency of its platform. Mach7 reduced operating expenses by 6% in H1 FY26 as part of its disciplined cost management, while maintaining a strong financial position with A$18.5 million in cash and no debt. This provides the company with the flexibility to execute on its commercial strategy and targeted investments. Key operational achievements during the period include scaling the product roadmap, transforming the sales and marketing model, and driving an operational overhaul to optimize costs. Mach7 also continued to make progress towards Medical Device Regulation (MDR) compliance and CE Mark, supporting its global regulatory pathways. Looking ahead, the company is focused on driving sales momentum, maintaining execution discipline, strengthening its leadership and organizational readiness, and leveraging its cost and structural advantages.

As H2 FY26 progresses, Mach7 has a refined strategy, stronger operational foundation and improving commercial momentum. The company remains focused on disciplined cost management while selectively investing in growth-supporting capabilities across sales execution, product development and platform scalability. Mach7 continues to prioritize financial discipline and efficient capital allocation, positioning it well to deliver against its strategy and capture emerging market opportunities.